13: The Smartest Doctor in the Room with Dean Mitchell, MD - Episode 1313: The Smartest Doctor in the Room with Dean Mitchell, MD - Episode 13
UK Health Radio Podcast
Dr Dean Mitchell talks with Dr Eric Klein about the Galleri multi-cancer blood test, explaining how it detects cancer signals in the bloodstream and who might benefit from it. The discussion looks at benefits, limits, false positives and how this kind of test fits alongside standard cancer screening.
49:40•8 Sept 2026
Are Multi-Cancer Blood Tests Ready for Everyday Use?
Episode Overview
- Galleri looks for cancer-related DNA methylation patterns in the blood, offering a single test that can suggest both the presence and likely origin of a cancer.
- Age is highlighted as the strongest overall risk factor for cancer, with a particular focus on screening adults aged 50 and above.
- The test is designed to sit alongside, rather than replace, traditional screenings such as mammography, colonoscopy and PSA testing.
- False positive rates with Galleri are reported as very low at the population level, though any positive result still requires targeted imaging and specialist follow-up.
- A negative result appears to lower short-term (one to two year) likelihood of being diagnosed with cancer, but does not remove the need for ongoing screening.
“The holy grail of medicine would be to have a simple blood test that detected cancers early enough to treat the cancer definitively.”
Curious about how others tackle scary health questions head-on? This conversation between Dr Dean Mitchell and urologist-oncologist Dr Eric Klein centres on one big question: are multi-cancer blood tests ready for everyday use? The episode focuses on Galleri, a blood test from Grail that checks for cancer signals across many organs at once. Dr Klein explains the science in plain English, breaking down methylation, gene expression and why cancer DNA shows up in the bloodstream.
As he puts it, "The holy grail of medicine would be to have a simple blood test that detected cancers early enough to treat the cancer definitively." You’ll hear how the test looks for shared patterns across different cancers, rather than single mutations, and why that matters for hard-to-spot cancers like pancreatic, ovarian and bile duct cancers.
They also tackle the big practical questions: who should consider testing (with a strong focus on age over 50), how often a negative result offers reassurance, and what happens when a result comes back positive. False positives, anxiety, follow-up scans and referrals are discussed openly, with Dr Klein stressing that Galleri is meant to sit alongside, not replace, tests like mammograms, PSAs and colonoscopies.
There’s also a clear emphasis on keeping patients supported, with clinical teams phoning doctors personally when a result is positive. The style is relaxed but detailed, ideal if you like hard science explained without jargon. If you’re someone who worries about family history, ageing, or catching illness early, this episode gives you lots to think about – and some calm, measured context for all the cancer headlines out there.
So, how do you feel about adding one more tool to the early-detection toolkit – and what questions would you ask your own doctor after hearing this?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.